PriceTargets.com logo

ObsEva - OBSV Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 09/6/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for OBSV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ObsEva Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OBSV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OBSV

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for ObsEva in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for OBSV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in ObsEva. This rating has held steady since August 2023, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/17/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/15/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/13/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/12/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/11/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/9/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/8/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/7/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/30/2022HC WainwrightDowngradeBuy ➝ NeutralLow
8/1/2022Canaccord Genuity GroupDowngradeBuy ➝ Hold$12.00 ➝ $1.00Low
7/28/2022Cantor FitzgeraldDowngradeOverweight ➝ NeutralLow
6/21/2022HC WainwrightReiterated RatingBuy$11.00Low
6/3/2022Cantor FitzgeraldInitiated CoverageOverweight$6.00High
5/23/2022HC WainwrightReiterated RatingBuy$11.00High
4/26/2022Canaccord Genuity GroupInitiated CoverageBuy$12.00High
3/28/2022AegisInitiated CoverageBuy$12.00High
3/28/2022HC WainwrightLower TargetBuy$15.00 ➝ $11.00Low
2/7/2022HC WainwrightReiterated RatingBuy$15.00Low
11/29/2021HC WainwrightLower TargetBuy$17.00 ➝ $15.00Low
9/17/2021WedbushReiterated RatingBuy$21.00High
9/15/2021HC WainwrightReiterated RatingBuy$17.00Medium
8/9/2021HC WainwrightReiterated RatingBuy$17.00Low
7/28/2021WedbushReiterated RatingBuy$21.00Low
7/2/2021WedbushReiterated RatingBuy$24.00N/A
1/12/2021WedbushReiterated RatingBuy$28.00Low
1/12/2021Leerink PartnersBoost TargetOutperform$4.00 ➝ $5.00Low
1/4/2021HC WainwrightLower TargetBuy$23.00 ➝ $17.00N/A
11/9/2020JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightMedium
10/5/2020HC WainwrightLower TargetBuy$36.00 ➝ $23.00High
8/14/2020WedbushReiterated RatingBuy$30.00High
7/7/2020Leerink PartnersLower TargetOutperform$7.00 ➝ $5.00High
7/7/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$18.00 ➝ $5.00High
7/6/2020BMO Capital MarketsDowngradeOutperform ➝ Market Perform$5.00 ➝ $4.00High
7/1/2020HC WainwrightReiterated RatingBuy$36.00Low
7/1/2020WedbushReiterated RatingBuy$30.00Low
6/5/2020HC WainwrightReiterated RatingBuy$36.00High
5/5/2020WedbushReiterated RatingBuy$30.00High
3/23/2020WedbushReiterated RatingBuy$40.00 ➝ $34.00Medium
3/23/2020HC WainwrightLower TargetBuy$40.00 ➝ $36.00Low
3/5/2020WedbushBoost TargetOutperform$36.00 ➝ $40.00High
1/21/2020WedbushReiterated RatingBuy$36.00High
1/21/2020HC WainwrightReiterated RatingBuy$40.00High
12/19/2019HC WainwrightReiterated RatingBuy ➝ Buy$36.00 ➝ $40.00High
12/10/2019Royal Bank of CanadaBoost TargetOutperform$18.00 ➝ $19.00High
12/2/2019HC WainwrightReiterated RatingBuy$44.00 ➝ $36.00Low
11/8/2019Credit Suisse GroupDowngradeOutperform ➝ Neutral$16.00 ➝ $4.00High
10/31/2019WedbushReiterated RatingBuy$38.00Medium
10/11/2019WedbushSet TargetBuy$38.00Low
(Data available from 9/7/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/10/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/11/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/10/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/10/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/9/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/9/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/8/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/7/2024

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
ObsEva logo
ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.01
Low: $0.00
High: $0.07

52 Week Range

Now: N/A

Volume

N/A

Average Volume

8,942,389 shs

Market Capitalization

$7.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.68

Frequently Asked Questions

What sell-side analysts currently cover shares of ObsEva?

The following Wall Street sell-side analysts have issued reports on ObsEva in the last year: StockNews.com.
View the latest analyst ratings for OBSV.

What is the current price target for ObsEva?

0 Wall Street analysts have set twelve-month price targets for ObsEva in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for ObsEva in the next year.
View the latest price targets for OBSV.

What is the current consensus analyst rating for ObsEva?

ObsEva currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for OBSV.

What other companies compete with ObsEva?

Other companies that are similar to ObsEva include Chembio Diagnostics, Lumos Pharma, Daré Bioscience, Akari Therapeutics and Unicycive Therapeutics. Learn More about companies similar to ObsEva.

How do I contact ObsEva's investor relations team?

ObsEva's physical mailing address is Chemin des Aulx 12 Plan-les-Ouates, Geneva V8, 1228. The company's listed phone number is (122) 552-3840 and its investor relations email address is [email protected]. The official website for ObsEva is www.obseva.com. Learn More about contacing ObsEva investor relations.